Insulet Corporation
Insulet Corporation Amends Credit Agreement to Lower Interest Rates
Summary
On January 24, 2024, Insulet Corporation amended its Credit Agreement to replace existing term loans with new ones at lower interest rates. The $487,500,000.00 in existing term loans were refinanced with new term loans with an interest rate margin reduced from 2.25% to 2.00% for base rate loans and from 3.25% to 3.00% for term SOFR loans, with a SOFR floor of 0.00%. The revolving facility interest rate margin was also reduced. The maturity of the loans remains unchanged. This amendment is part of the company's financial strategy to manage debt costs.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement